Plavix (clopidogrel) NDC 0024-1332

NDC codes

FDA NDC Directory

Product NDC (as listed)0024-1332Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00024-1332Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0024-1332-30	00024133230	3 BLISTER PACK in 1 CARTON (0024-1332-30) / 10 TABLET, FILM COATED in 1 BLISTER PACKMarketed from Jul 13, 2020

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Plavix
Generic name (nonproprietary): clopidogrel
Active ingredients: Clopidogrel bisulfate — 300 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Sanofi-Aventis U.S. LLC
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 020839
Marketing start: May 9, 2009
Listing expires: Dec 31, 2026
Other FDA classes: Cytochrome P450 2C8 Inhibitors (Mechanism)Decreased Platelet Aggregation (Physiologic effect)P2Y12 Receptor Antagonists (Mechanism)
Identifiers: Product ID 0024-1332_ed60a9e7-49f4-469c-bb7a-08e1bb6057e2SPL ID ed60a9e7-49f4-469c-bb7a-08e1bb6057e2SPL set ID de8b0b67-eb25-4684-83b5-7ad785314227RxCUI 213169, 309362, 749196, 749198UNII 08I79HTP27
Pharmacologic class: P2Y12 Platelet Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400024133230 followed by a unit qualifier and the quantity

Package 00024-1332-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 30, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Plavix is a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome – For patients with non–ST-segment elevation ACS (unstable angina [UA]/non–ST-elevation myocardial infarction [NSTEMI]), Plavix has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) – For patients with ST-elevation myocardial infarction (STEMI), Plavix has been shown to reduce the rate of MI and stroke. ( 1.1 ) Recent MI, recent stroke, or established peripheral arterial disease. Plavix has been shown to reduce the rate of MI and stroke. ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) Plavix is indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non–ST-segme…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 020839

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 020839
Product	Strength	Form · route	Labeler	Product NDC
Plavixclopidogrel	Clopidogrel bisulfate 75 mg/1	Tablet, Film coatedOral	Sanofi-Aventis U.S. LLC	0024-1171